Yuchun Lee - Apr 6, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 6, 2022
Transactions value $
-$766,804
Form type
4
Date filed
4/8/2022, 05:57 PM
Previous filing
Apr 6, 2022
Next filing
Apr 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $163K +2K +106.67% $81.54 3.88K Apr 6, 2022 Direct
transaction VRTX Common Stock Sale -$4.55K -17 -0.44% $267.57 3.86K Apr 6, 2022 Direct F1
transaction VRTX Common Stock Sale -$81.2K -300 -7.78% $270.67 3.56K Apr 6, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$435K -1.6K -44.97% $271.78 1.96K Apr 6, 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$22.6K -83 -4.24% $272.84 1.88K Apr 6, 2022 Direct F1, F2, F5
transaction VRTX Common Stock Options Exercise $163K +2K +106.67% $81.54 3.88K Apr 7, 2022 Direct
transaction VRTX Common Stock Sale -$114K -417 -10.76% $272.76 3.46K Apr 7, 2022 Direct F1, F2, F7
transaction VRTX Common Stock Sale -$137K -500 -14.46% $273.78 2.96K Apr 7, 2022 Direct F1, F2, F8
transaction VRTX Common Stock Sale -$70.5K -256 -8.65% $275.26 2.7K Apr 7, 2022 Direct F1, F2, F9
transaction VRTX Common Stock Sale -$201K -727 -26.91% $276.37 1.98K Apr 7, 2022 Direct F1, F2, F10
transaction VRTX Common Stock Sale -$27.7K -100 -5.06% $277.02 1.88K Apr 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -2K -12.5% $0.00 14K Apr 6, 2022 Common Stock 2K $81.54 Direct F6
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -2K -14.29% $0.00 12K Apr 7, 2022 Common Stock 2K $81.54 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
F2 Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $270.67 (range $270.42 to $270.88).
F4 Open market sales reported on this line occurred at a weighted average price of $271.78 (range $271.43 to $272.33).
F5 Open market sales reported on this line occurred at a weighted average price of $272.84 (range $272.56 to $272.97).
F6 Fully vested.
F7 Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.50 to $273.28).
F8 Open market sales reported on this line occurred at a weighted average price of $273.78 (range $273.52 to $273.98).
F9 Open market sales reported on this line occurred at a weighted average price of $275.26 (range $274.64 to $275.43).
F10 Open market sales reported on this line occurred at a weighted average price of $276.37 (range $275.94 to $276.82).